mrx 4

Contezolid acefosamil (MRX-4), an orally active prodrug, is metabolized into Contezolid (MRX-I), an oxazolidinone derivative with potent in vitro efficacy against multidrug-resistant Gram-positive bacteria, including MRSA.

Contezolid acefosamil sodium (MRX-4) is a novel orally active oxazolidinone antibiotic under investigation for the treatment of complicated skin and soft tissue infections (cSSTI) caused by drug-resistant Gram-positive bacteria. It possesses strong efficacy against these pathogens while significantly minimizing the risks of myelosuppression and monoamine oxidase inhibition (MAOI) [1][2].